CARDIOVASCULAR EFFECTS OF ALDOSTERONE
https://doi.org/10.24884/1561-6274-2008-12-2-36-38
Abstract
The work contains data of the effects of aldosterone when binding with epithelial and non-epithelial mineral corticoid receptors. The pathophysiological role of this steroid hormone is shown in the development of cardiovascular complications in chronic diseases of the kidneys as well. The data of experimental and clinical investigations are presented demonstrating the ability of aldosterone to cause fibrosis of the myocardium and vessels
About the Authors
A. Zh. Karabaeva
Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова
Russian Federation
Russian Federation
A. M. Essaian
Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова
Russian Federation
Russian Federation
I. G. Kayukov
Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова
Russian Federation
Russian Federation
References
1. Christ M, Douwes K, Eisen C et al. Rapid non-genomic effects of aldosterone on sodium transport in rat vascular smooth muscle cells: involvement of the Na+ / H+ antiport. Hypertension 1995; 25: 117-123
2. Camargo MJ, von Lutterotti N, Campbell JrWG et al. Control of blood pressure and end-organ damage in maturing salt-loaded stroke-prone spontaneously hypertensive rats by oral angiotensin II receptor blockade. J Hypertens 1993; 11: 31–40
3. Duprez D, de Buyzere M, Rietzchel ER, Clement DL. Aldosterone and vascular damage. Curr Hypertens Rep 2000; 2; 327-334
4. Epstein M. Aldosterone receptor blockade and the role of eplerenone: evolving perspectives. Nephrol Dial Transpl 2003; 18: 1984-1992
5. Foster RH, MacFarlane CH, Bustamante MO. Recent progress in understanding aldosterone secretion. Gen Pharmacol 1997; 28: 647-651
6. Fuller PJ. Aldosterone’s effects and mechanism of action. Curr Opin Endocrinol Diabetes 1997; 4: 218-224
7. Ebata S, Muto S, Okada K et al. Aldosterone activates Na+ / H+ exchange in vascular smooth muscle cells by non-genomic and genomic mechanisms. Kidney Int 1999; 56: 1400-1412
8. Gekle M, Freudinger R, Mildenberger S, Silbernagl S. Rapid actions of aldosterone on cells from renal epithelium: the possible role of EGF-receptor signaling. Steroids 2002; 67: 499–504
9. Halimi J-M, Mimram A. Albuminuria in untreated patients with primary aldosteronism or essential hypertension. J Hypertens 1995; 13: 1801–1802
10. Jalil JE, Janicki JS, Pick R, Weber KT. Coronary vascular remodeling and myocardial fibrosis in the rat with renovascular hypertension: response to captopril. Am J Hypertens 1991; 4: 51–55
11. Karin M. New twists in gene regulation by glucocorticoid receptor: is DNA binding dispensable? Cell 1998; 93: 487-490
12. Laragh JH, Sealy JE. The renin-angiotensin-aldosterone system in hypertensive disorders: a key to two forms of arteriolar constriction and a possible clue to risk of vascular injury (heart attack and stroke) and prognosis. In: Laragh JH, Brenner BM (eds) Hypertension1990; Pathophysiology, Diagnosis, and Management. Raven Press, New York, 1329-1348
13. Nishimura M, Uzu T, Fuji T et al. Cardiovascular complications in patients with primary aldosteronism. Am J Kidney Dis 1999; 33: 261-266
14. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341:709-717
15. Rossi GP, Sachetto A, Visentin P et al. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 1996; 27: 1039-1045
16. Rocha R, Martin-Berger CL, Yang P et al. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 2002; 143: 4828-4836
17. Stier Jr CT, Chander PN, Gutstein WH et al. Therapeutic benefit of captopril in salt-loaded stroke-prone spontaneously hypertensive rats is independent of hypotensive effect. Am J Hypertens 1991; 4: 680-687
18. Stier Jr CT, Adler LA, Levine S, Chander PN. Stroke prevention by losartan in stroke-prone spontaneously hypertensive rats. J Hypertens 1993; 11 [Suppl 3]: S37-S42
19. Silvestre J-S, Heymes C, Oubenaisso A et al. Activation of cardiac aldosterone production in rat myocardial infarction. Effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999; 99: 2694-2701
20. Schiffrin EL, Franks DJ, Gutkowska J. Effect of aldosterone on vascular angiotensin II reseptors in the rat. Can J Physiol Pharmacol 1985; 63: 1522-1527
21. Takeda R, Matsubara T, Miyamori I et al. Research Committee of Disorders of Adrenal Hormones in Japan. Vascular complications in patients with aldosterone producing adenoma in Japan: comparative study with essential hypertension. J Endocrinol Invest 1995; 18: 370-373
22. Wehling M. Non-genomic actions of steroid hormones. Trends Endocrinol Metab 1994; 5: 347-353
23. Wehling M, Neylon CB, Fullerton M et al. Non-genomic effects of aldosterone on intracellular calcium in vascular smooth muscle cells. Circ Res 1995; 76: 973-979
24. Wehling M, Spes CH, Win N et al. Rapid cardiovascular action of aldosterone in man. J Clin Endocrinol Metab 1998; 83: 3517-3522
25. Rocha R, Stier CTJ, Kifor I et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000; 141: 3871-3878
26. Connell JMC, Davies E. The new biology of aldosterone. Journal of Endocrinology 2005; 186: 1-20
Review
For citations:
Karabaeva A.Zh., Essaian A.M., Kayukov I.G. CARDIOVASCULAR EFFECTS OF ALDOSTERONE. Nephrology (Saint-Petersburg). 2008;12(2):36-38. (In Russ.) https://doi.org/10.24884/1561-6274-2008-12-2-36-38
Views:
361
Email this article 